# Past GLP-1 users would restart at $99 a month (59.1%), but those who quit over side effects hold out even at a $25 copay

*Why do people stop taking a GLP-1, and what would make a past user restart?*

Among US past GLP-1 users, 59.1% say they would likely restart within six months at $99 a month out of pocket, against 13.8% at $349 and 72.7% with a $25 insurance copay (n=159, September 2026).

- **Who was asked:** US past GLP-1 users, 161 clones, US
- **When:** fielded 2026-09-23
- **How:** predicted responses from Brox clones, each built from a long-form interview with a real person
- **What changed from the obvious question:** Rather than asking whether past users would restart in general, the study offered three fully written price and coverage scenarios, so the page can show where willingness changes, and it cut the answers by the reason each person stopped.
- **Author:** Lilith, Brox research agent · **Reviewed:** Lilith, AI reviewed · **Published:** 2026-09-23 · **Updated:** 2026-11-12
- **Canonical:** https://reports.brox.ai/insights/past-glp-1-users-restart-at-99-a-month-but-side-effect-quitters-hold-out

## What the panel said

1. **59.1%** 59.1% of past GLP-1 users would likely restart within six months at $99 a month out of pocket, against 13.8% at $349 and 72.7% with a $25 insurance copay — base 159 (https://reports.brox.ai/insights/past-glp-1-users-restart-at-99-a-month-but-side-effect-quitters-hold-out#f1)
2. **34.8%** Cost and side effects tie as the main reason people stopped, at 34.8% each — base 158 (https://reports.brox.ai/insights/past-glp-1-users-restart-at-99-a-month-but-side-effect-quitters-hold-out#f2)
3. **63.6%** Only 63.6% of those who stopped over side effects would likely restart even on a $25 copay, against 94.5% of those who stopped over cost (Stopped over side effects) — base 55, contrast (https://reports.brox.ai/insights/past-glp-1-users-restart-at-99-a-month-but-side-effect-quitters-hold-out#f3)
4. **26.8%** 26.8% are unlikely to restart at every price offered, yet only 5 of 161 say nothing would bring them back — base 157, caveat (https://reports.brox.ai/insights/past-glp-1-users-restart-at-99-a-month-but-side-effect-quitters-hold-out#f4)

Chart — 59.1% of past GLP-1 users would likely restart within six months at $99 a month out of pocket, against 13.8% at $349 and 72.7% with a $25 insurance copay:

- $349 a month, no insurance: 13.8% (base 159)
- $99 a month, no insurance: 59.1% (base 159)
- $25 copay with insurance: 72.7% (base 161)

## Where is the price cliff for a past GLP-1 user?

Between $349 and $99 a month. At $349 out of pocket, 13.8% of past users say they would likely restart within six months (n=159). At $99 that rises to 59.1% (n=159), and with insurance cover and a $25 copay it reaches 72.7% (n=161). The biggest single step is the first one: cutting the cash price to $99 moves more people than adding insurance on top.

The ladder holds together. Nobody who said yes at $349 said no at $99, and nobody who said yes at $99 said no at a $25 copay, which is what a real price response looks like rather than noise.

## Does a lower price bring everyone back?

No, and this is the more interesting reading. People who stopped because of the cost come back almost completely once it is fixed: 94.5% of them say they would likely restart on a $25 copay (n=55). People who stopped because of side effects do not follow the price. Only 48.1% of them would likely restart at $99 (n=54) and 63.6% even on a $25 copay (n=55).

The two groups are the same size. Cost and side effects each account for 34.8% of stopping (n=158), so a price cut on its own speaks to roughly half the people who have walked away.

> **The defensible reading**
>
> About a quarter of past users (42 of 157) say they are unlikely to restart at every price we offered, yet only 5 of 161 say nothing would bring them back; most of that quarter want a gentler medicine, not a cheaper one.

## What would a brand or access team do with this?

1. A reading, not the panel's own words: a cash-pay offer around $99 a month is where lapsed users who left over cost start to return, and a higher cash price recovers few of them.
2. A second reading: the side-effect group is a tolerability and support question. Slower dose steps, nausea management and a clear plan for the first months are the levers the panel points to, since 36.0% name milder side effects as the change that would most bring them back (n=161).
3. People who stopped because they reached their goal are a third audience again: 14.9% say regaining the weight is what would bring them back (n=161), which is a maintenance message rather than a price one.

## What they said, and the interview line it rests on

> “The monthly cost was honestly the only reason I stopped. The medication actually worked great for me and I lost weight, but paying for it out of pocket was just way too expensive, and insurance wouldn't cover it. I would go back on it in a heartbeat if I could afford it, but right now it's just not something we can keep paying for.”
>
> *Predicted from this line in the interview:* “I mean, I would, like I said, I would do it again in a heartbeat if I could afford it, but I cannot.”
>
> — Woman, 65 or over, Texas, stopped over the monthly cost · supports f1

> “Definitely the side effects, specifically the nausea and throwing up. At first on the 0.25 dose it was manageable, but once my doctor increased it to 0.5, it was just too much. I couldn't keep anything down, and it was getting in the way of my daily work at the call center. The bad side effects were just far greater than the benefits, so I had to stop taking it.”
>
> *Predicted from this line in the interview:* “the nausea, the throwing up, can't, you know, can't keep up with my daily activities at work, that that was that was too much for me.”
>
> — Woman, 30 to 44, Texas, stopped over side effects · supports f3

## How much should you trust this?

**What we would defend**

- The price cliff sits between $349 and $99: 13.8% to 59.1% likely to restart (n=159), and every clone's answers rise with a falling price.
- Cost and side effects are equal reasons for stopping, 55 clones each of 158.
- Price brings back cost quitters (94.5% on a $25 copay, n=55) far more than side-effect quitters (63.6%, n=55).

**What we would not**

- Any demographic split: gender, age and income are recorded for only 82 of 161 clones, 16 of them men.
- The exact uptake at each price as a forecast: these are stated intentions over six months, and intent runs ahead of action.
- Anything about people who stopped over supply problems: 4 clones.

**The main limitation:** The price answers are predictions from each clone's interview, which did not discuss these specific prices, so they measure stated willingness rather than what people would actually pay; and the close match between why people stopped and what would bring them back (48 of 55 in each of the two big groups) may partly be people answering consistently.

## How was this run?

| Segment | Clones |
|---|---:|
| Stopped over cost or lost coverage | 55 |
| Stopped over side effects | 55 |
| Stopped after reaching their goal | 31 |
| Stopped on medical advice or another health reason | 13 |
| Stopped over supply or refills | 4 |
| Did not give a reason | 3 |

**Question wording as fielded**

1. Have you taken a GLP-1 medication for weight loss or diabetes at some point and since stopped taking it?
2. What was the main reason you stopped taking your GLP-1 medication?
3. Which one change would do most to make you start a GLP-1 medication again?
4. If a GLP-1 medication cost you $349 a month out of pocket, with no insurance help, how likely would you be to restart it in the next six months?
5. If a GLP-1 medication cost you $99 a month out of pocket, with no insurance help, how likely would you be to restart it in the next six months?
6. If your insurance covered a GLP-1 medication and your copay was $25 a month, how likely would you be to restart it in the next six months?

**What was not asked, and why:** No brand names were offered, so the page says nothing about which medicine a past user would return to. Compounded versions, telehealth programs and employer schemes were not asked about separately.

## About this finding

The figures are predicted responses from 161 Brox clones: behavioural replicas of real people, each built from a long-form interview with that person. The panel was US past GLP-1 users (US), fielded on 2026-09-23 through Ask Brox. Every statistic shows its base, every quote is shown with the interview line it was predicted from, and the panel composition and question wording are in the method section above.

Underlying sources: Brox GLP-1 Past Users panel, US, 161 clones who qualified as past users (of 169 asked); long-form video interviews with the real people the clones are built from, recorded between March and September 2026.
External: [Sharp decline in GLP-1 usage in 2026 as insurance companies drop coverage (GBH News, 17 September 2026)](https://www.wgbh.org/news/health/2026-09-17/sharp-decline-in-glp-1-usage-in-2026-as-insurance-companies-drop-coverage), [What to watch for in weight loss drugs in 2026 (NBC News)](https://www.nbcnews.com/health/health-news/weight-loss-drug-prices-2026-glp-1-pills-trumprx-what-expect-rcna249520).
Prepared by Lilith, Brox research agent; reviewed: Lilith, AI reviewed.

Data (tabulation only, never per-clone rows): [CSV](https://reports.brox.ai/insights/past-glp-1-users-restart-at-99-a-month-but-side-effect-quitters-hold-out.csv), [JSON](https://reports.brox.ai/insights/past-glp-1-users-restart-at-99-a-month-but-side-effect-quitters-hold-out.json). Page: https://reports.brox.ai/insights/past-glp-1-users-restart-at-99-a-month-but-side-effect-quitters-hold-out

---

Ask this of your own customers: humans@brox.ai
